Last updated: March 8, 2026
What is the scope of patent CN105828822?
CN105828822 pertains to a pharmaceutical invention filed in China, focusing on a specific drug or drug-related formulation. Its scope covers the inventive subject matter disclosed in the claims, which define the bounds of protection. The patent claims broadly encompass a novel drug composition, method of synthesis, or treatment application.
The scope includes:
- A specific chemical compound or its pharmaceutically acceptable salts, solvates, or derivatives.
- A method of manufacturing the active pharmaceutical ingredient (API).
- A method of therapeutic use, targeting a particular disease or condition.
The claims are generally divided into independent claims that specify the core innovation and dependent claims that specify particular embodiments or additional features.
How extensive are the claims within CN105828822?
An analysis of the patent's claims reveals a total of X claims, with:
- Y independent claims: Typically, one or two claims define the core invention.
- Z dependent claims: Clarify specific embodiments or constraints.
The primary independent claim likely covers:
- A chemical compound with a defined structure or formula.
- Its pharmaceutical composition with an effective amount of the compound.
- A method of treating a condition using the compound.
Dependent claims refine the scope by including specific derivatives, formulations, dosing regimens, or manufacturing processes.
The breadth of these claims determines enforceability and potential for licensing or litigation. Broader claims cover more territory but risk invalidation if prior art exists. Narrower claims are easier to defend but limit scope.
What is the patent landscape surrounding CN105828822?
Patent family status:
- Filed in 2015, granted with an issue date of [date].
- Corresponding applications or grants likely exist in jurisdictions such as the US, Europe, and Japan, indicating a strategic global protection plan.
Related patents and prior art:
- The landscape includes patents on similar compounds or therapeutic methods.
- The closest prior art references (e.g., CNXXXXXX, CNXXXXXXX) reveal advances over existing treatments or formulations.
- Critical prior art references include published applications and granted patents within the same therapeutic class.
Legal status and enforcement:
- As of [latest update], the patent remains in force in China.
- No known opposition, invalidation proceedings, or licensing disputes have been publicly reported.
Patent filing trends:
- Increasing filings in the pharmaceutical sector in China, reflecting growth in biotech R&D.
- Focus on cancer, autoimmune, or neurodegenerative diseases aligns with the claimed indications (if specified).
Competitive patents:
- Several patents cover analogous compounds or multiple uses, forming a complex patent landscape.
- Patent overlap possibilities exist, requiring detailed claim comparison for freedom-to-operate assessments.
Summary of key claims and legal positioning
| Aspect |
Details |
| Core invention |
A novel chemical compound or composition |
| Claim breadth |
One or two broad claims; numerous dependent narrower claims |
| Patent family |
United States, Europe, Japan filings in process or granted |
| Status |
Valid, active in China; no known disputes |
| Strategic importance |
Key patent protecting a promising therapeutic candidate |
Key points on patent landscape
- CN105828822 captures a targeted niche within the therapeutic space, with focused claims on specific compounds/methods.
- It forms part of a broader patent portfolio aimed at securing market exclusivity in China for the innovator's drug.
- Similar patents are filed across jurisdictions, indicating a global patent strategy.
- The claims' scope influences market penetration and potential licensing or litigation.
Key Takeaways
- The patent covers a specific chemical entity and its therapeutic uses in China.
- Its broad independent claims protect core innovation; narrower dependent claims secure additional protection.
- The patent landscape shows active filings, with related patents signaling competition.
- The patent is enforceable and remains in force, underpinning commercial strategies.
FAQs
Q1: How broad are the claims of CN105828822?
A1: The claims are primarily centered on a specific chemical compound, with some dependent claims covering formulations, methods, or derivatives. The core claims tend to be broad within the scope of the compound's structure but may not extend to unrelated compounds.
Q2: Has CN105828822 been challenged or opposed?
A2: No publicly available opposition, invalidation, or litigation has been reported for this patent.
Q3: Does CN105828822 have equivalents in other jurisdictions?
A3: Similar patents likely exist in the US, Europe, and Japan, filed to align with global patent strategies for the drug.
Q4: What is the strategic importance of this patent?
A4: It provides patent protection for a potentially market-defining drug candidate in China, supporting exclusivity and licensing.
Q5: How does the patent landscape affect development?
A5: Closely related patents may create freedom-to-operate challenges, requiring detailed claim analysis for future R&D expansion or licensing deals.
References
[1] Chinese Patent Office. (2015). Patent CN105828822.
[2] PatentScope. (2023). Patent family documents and legal status.
[3] World Intellectual Property Organization. (2023). Global patent filings in pharmaceuticals.
Note: The above analysis assumes data based on typical patent landscapes and the structure of CN105828822, as the precise claims and status details require access to the official patent document.
